Interventionelle Behandlung der Aortenklappe – Update und Herausforderungen 2019

Abstract

Aortic valve stenosis is the most common valvular heart disease requiring treatment in Europe. Transcatheter aortic valve implantation (TAVI) has already been established as a standard therapy in patients with high but also intermediate risk.

In the meantime, it is even being performed more frequently than surgical replacement in Germany.

This article presents current data, indications and future challenges.

Die Aortenklappenstenose ist in Europa der häufigste behandlungsbedürftige Herzklappenfehler. Als Standardtherapie hat sich der Katheter-gestützte Aortenklappenersatz bei Patienten mit hohem und intermediärem operativem Risiko bereits etabliert. Mittlerweile wird er in Deutschland sogar häufiger durchgeführt als der konventionell-chirurgische Klappenersatz. Aktuelle Datenlage, Indikationen und Herausforderungen stellt dieser Beitrag vor.

Schlüsselwörter

TAVI - paravalvuläre Leckagen - Schrittmacher - bikuspide Aortenklappe - Schlaganfall

Key words

TAVI - paravalvular leaks - pacemaker - bicuspid aortic valve - stroke

• Literatur

• 1 Ross jr J, Braunwald E. Aortic stenosis. Circulation 1968; 38: 61-67
• 2 Baumgartner H, Falk V, Bax JJ. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739-2791 . doi:10.1093/eurheartj/ehx391
• 3 Popma JJ, Deeb GM, Yakubov SJ. et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019; DOI: 10.1056/NEJMoa1816885.
• 4 Mack MJ, Leon MB, Thourani VH. et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019; DOI: 10.1056/NEJMoa1814052.
• 5 Sondergaard L, Ihlemann N, Capodanno D. et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll Cardiol 2019; 73: 546-553 . doi:10.1016/j.jacc.2018.10.083
• 6 Deutsch MA, Erlebach M, Burri M. et al. Beyond the five-year horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices. EuroIntervention 2018; 14: 41-49 . doi:10.4244/eij-d-17-00603
• 7 Tchetche D, de Biase C, van Gils L. et al. Bicuspid Aortic Valve Anatomy and Relationship With Devices: The BAVARD Multicenter Registry. Circ Cardiovasc Intervent 2019; 12: e007107 . doi:10.1161/circinterventions.118.007107
• 8 Yoon SH, Bleiziffer S, De Backer O. et al. Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis. J Am Coll Cardiol 2017; 69: 2579-2589 . doi:10.1016/j.jacc.2017.03.017
• 9 Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55: 2789-2800 . doi:10.1016/j.jacc.2009.12.068
• 10 Das R, Puri R. Transcatheter Treatment of Bicuspid Aortic Valve Disease: Imaging and Interventional Considerations. Front Cardiovasc Med 2018; 5: 91 . doi:10.3389/fcvm.2018.00091
• 11 Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 2007; 133: 1226-1233 . doi:10.1016/j.jtcvs.2007.01.039
• 12 Giustino G, Sorrentino S, Mehran R. et al. Cerebral Embolic Protection During TAVR: A Clinical Event Meta-Analysis. J Am Coll Cardiol 2017; 69: 465-466 . doi:10.1016/j.jacc.2016.12.002
• 13 Testa L, Latib A, Casenghi M. et al. Cerebral Protection During Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta-Analysis. J Am Heart Assoc 2018; 7 DOI: 10.1161/jaha.117.008463.
• 14 van Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 2018; 39: 2003-2013 . doi:10.1093/eurheartj/ehx785
• 15 Mohr FW, Holzhey D, Mollmann H. et al. The German Aortic Valve Registry: 1-year results from 13680 patients with aortic valve disease. Eur J Cardio-thora Surg 2014; 46: 808-816 . doi:10.1093/ejcts/ezu290
• 16 Gaede L, Kim WK, Liebetrau C. et al. Pacemaker implantation after TAVI: predictors of AV block persistence. Clin Res Cardiol 2018; 107: 60-69 . doi:10.1007/s00392-017-1158-2
• 17 Tuzcu EM, Kapadia SR, Vemulapalli S. et al. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry. J Am Coll Cardiol 2018; 72: 370-382 . doi:10.1016/j.jacc.2018.04.074
• 18 Bleiziffer S, Erlebach M, Simonato M. et al. Incidence, predictors and clinical outcomes of residual stenosis after aortic valve-in-valve. Heart 2018; 104: 828-834 . doi:10.1136/heartjnl-2017-312422
• 19 Ribeiro HB, Webb JG, Makkar RR. et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 2013; 62: 1552-1562 . doi:10.1016/j.jacc.2013.07.040
• 20 Wernly B, Eder S, Navarese EP. et al. Transcatheter aortic valve replacement for pure aortic valve regurgitation: “on-label” versus “off-label” use of TAVR devices. Clin Res Cardiol 2019; DOI: 10.1007/s00392-019-01422-0.